KR900700130A - 종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법 - Google Patents

종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법

Info

Publication number
KR900700130A
KR900700130A KR1019890702004A KR890702004A KR900700130A KR 900700130 A KR900700130 A KR 900700130A KR 1019890702004 A KR1019890702004 A KR 1019890702004A KR 890702004 A KR890702004 A KR 890702004A KR 900700130 A KR900700130 A KR 900700130A
Authority
KR
South Korea
Prior art keywords
vaccine
tumor
virus
immunotherapy
state
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019890702004A
Other languages
English (en)
Korean (ko)
Inventor
쉬르마춰 볼커
Original Assignee
에이치.씨.에이치. 주르 하우젠 알.그룬발트
도이취스 크렙스포르슝스젠트룸
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6348527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900700130(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에이치.씨.에이치. 주르 하우젠 알.그룬발트, 도이취스 크렙스포르슝스젠트룸 filed Critical 에이치.씨.에이치. 주르 하우젠 알.그룬발트
Publication of KR900700130A publication Critical patent/KR900700130A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019890702004A 1988-03-01 1989-02-27 종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법 Withdrawn KR900700130A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3806565A DE3806565A1 (de) 1988-03-01 1988-03-01 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DEP3806565.7 1988-03-01
PCT/EP1989/000186 WO1989007946A1 (fr) 1988-03-01 1989-02-27 Vaccins tumoraux modifies viralement pour immunotherapie de metastases tumorales

Publications (1)

Publication Number Publication Date
KR900700130A true KR900700130A (ko) 1990-08-11

Family

ID=6348527

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890702004A Withdrawn KR900700130A (ko) 1988-03-01 1989-02-27 종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법

Country Status (10)

Country Link
US (1) US5273745A (cg-RX-API-DMAC7.html)
EP (1) EP0331102B1 (cg-RX-API-DMAC7.html)
JP (1) JPH02504034A (cg-RX-API-DMAC7.html)
KR (1) KR900700130A (cg-RX-API-DMAC7.html)
AT (1) ATE90877T1 (cg-RX-API-DMAC7.html)
AU (1) AU3188989A (cg-RX-API-DMAC7.html)
DE (2) DE3806565A1 (cg-RX-API-DMAC7.html)
DK (1) DK541889D0 (cg-RX-API-DMAC7.html)
ES (1) ES2042828T3 (cg-RX-API-DMAC7.html)
WO (1) WO1989007946A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE4204132C2 (de) * 1991-02-12 1997-12-18 Rudolf Dr Pekar Aufbereitung für die Gewinnung von Vakzinen für eine Immuntherapie
ATE230615T1 (de) * 1991-10-04 2003-01-15 Whitehead Biomedical Inst Regulierung der systemischen immunantworten mittels zytokinen und antigenen
ES2310580T3 (es) 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
DE19506483A1 (de) * 1995-02-24 1996-08-29 Jens Dr Dr Atzpodien Lyophilisat-Vakzine
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0805207A1 (en) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression plasmid for tumor rejection
EP0951475B1 (en) * 1996-05-03 2003-07-16 Thomas Jefferson University Metastatic colorectal cancer vaccine
NZ330995A (en) * 1996-10-04 2000-12-22 Univ Jefferson Generation of T cells mediating an immune response and use for treating cancer
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
RU2172182C1 (ru) * 2000-07-27 2001-08-20 Бритов Василий Александрович Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
WO2004096244A1 (en) * 2003-05-02 2004-11-11 Md Bioalpha Co. Ltd. Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性gitrリガンド発現細胞
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection

Also Published As

Publication number Publication date
ES2042828T3 (es) 1993-12-16
ATE90877T1 (de) 1993-07-15
DE3806565A1 (de) 1989-09-14
DE58904760D1 (de) 1993-07-29
DK541889A (da) 1989-10-31
WO1989007946A1 (fr) 1989-09-08
AU3188989A (en) 1989-09-22
DE3806565C2 (cg-RX-API-DMAC7.html) 1991-04-25
EP0331102A1 (de) 1989-09-06
US5273745A (en) 1993-12-28
DK541889D0 (da) 1989-10-31
EP0331102B1 (de) 1993-06-23
JPH02504034A (ja) 1990-11-22

Similar Documents

Publication Publication Date Title
DE58904760D1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen.
ATE203421T1 (de) Keime von kobalt-palladium zur thermischen behandlung von tumoren
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
IL98957A0 (en) Immunotherapy with interleukin-7
BR0206985A (pt) Anticorpos modificados e métodos de uso
AU584864B2 (en) Method of culturing freeze-dried microorganisms
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
DK0781092T3 (da) Nucleinsyre som koder for adenovirus E1A-polypeptid til sensibilisering af tumorceller for kemoterapi eller bestråling
RU94022017A (ru) Способ лечения акне или псевдофолликулита бороды, способ получения композиции, применение ингибитора фермента орнитиндекарбоксилазы для лечения акне или псевдофолликулита бороды
KR960700746A (ko) 헬리코박터 피롤리 관련 위십이지장 질환의 치료 방법(treatment of h. pylori associated gastroduodenal disease)
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
Pollard et al. Radiation action on DNA in bacteria: Effect of oxygen
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
GB1508878A (en) Hepatitis a antigen
ES8707565A1 (es) Un procedimiento para producir un anticuerpo monoclonal
AR015237A1 (es) Una composicion de membranas celulares tumorales modificadas con hapteno, metodo para obtenerlas y su uso.
ES8604774A1 (es) Procedimiento de preparar agentes cosmeticos para el trata- miento de la piel
AU1256495A (en) Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
SE8201128L (sv) Forfarande for reproduktion av virulent treponema pallidum i vevnadsk ultur
Gerweck et al. The lack of correlation between heat and radiation sensitivity in mammalian cells
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
ES2047946T3 (es) Metodos de cultivos celulares para producir proteina c activada.
DE69636456D1 (de) In-vitro verpackung von adeno-assozierten virus dns
SU604554A1 (ru) Способ пластики красной каймы губ

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19891031

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid